Probiotic Trial Reports Lower pTau181 in Alzheimer's

Buzzline

A randomized trial in South Korea tested a three-strain probiotic in 87 older adults with early cognitive impairment. After 24 weeks, probiotic users scored better than placebo on several thinking tests and had lower levels of pTau181, a blood marker linked to Alzheimer's. They also had better dementia rating scores and a bigger drop in an inflammation marker. Researchers call the results exciting but preliminary because the trial was small and cannot show that tau tangles in the brain were reduced. Larger trials are planned.  Disclosure: This video contains stock footage and content created or enhanced using AI-assisted tools.

Transcript

00:00A randomized trial in South Korea tested a probiotic in older adults with early cognitive

00:05impairment. The product, KLP301, contains three bacterial strains. In total, 87 participants

00:12completed 24 weeks of daily supplementation or placebo. Probiotic users scored better than

00:18placebo on several cognitive tests. They also had significantly better clinical dementia rating

00:23scores. Levels of PTA181, a blood marker associated with Alzheimer's, fell significantly in the

00:31probiotic group. The marker stayed relatively stable in the placebo group. A marker of inflammation

00:36called IL-1 beta declined more with the probiotic. Researchers described the findings as exciting,

00:43but still preliminary. Only 40 participants finished the probiotic arm, and 47 finished placebo.

00:49The trial does not show that probiotics reduce tau tangles in the brain. The authors call

00:54for larger, longer trials with brain imaging. The results were published in the Journal of

00:59Alzheimer's Disease. Disclosure. This video contains stock footage and content created or enhanced

01:03using AI-assisted tools.

Category

Transcript

Recommended